Immutep to Participate at the Jefferies Healthcare Conference
June 07 2023 - 8:00AM
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the
Company”), a clinical-stage biotechnology company developing novel
LAG-3 immunotherapies for cancer and autoimmune disease, today
announces Marc Voigt, CEO of Immutep, will be presenting at the
Jefferies Healthcare Conference being held on June 7-9, 2023 in New
York City, NY.
Event: |
Jefferies Healthcare Conference |
Date: |
Thursday, 8 June
2023 |
Time: |
10:00am – 10:25am (ET) |
A live webcast of Mr. Voigt’s presentation will
be available here and after the conference under the Events page
within the Investors & Media section of Immutep’s website.
About ImmutepImmutep is a
clinical stage biotechnology company developing novel LAG-3
immunotherapy for cancer and autoimmune disease. We are pioneers in
the understanding and advancement of therapeutics related to
Lymphocyte Activation Gene-3 (LAG-3), and our diversified product
portfolio harnesses its unique ability to stimulate or suppress the
immune response. Immutep is dedicated to leveraging its expertise
to bring innovative treatment options to patients in need and to
maximise value for shareholders. For more information, please visit
www.immutep.com.
Australian
Investors/Media:Catherine Strong, Citadel-MAGNUS+61 (0)406
759 268; cstrong@citadelmagnus.com
U.S. Media:Chris Basta, VP,
Investor Relations and Corporate Communications+1 (631) 318 4000;
chris.basta@immutep.com
Immutep (NASDAQ:IMMP)
Historical Stock Chart
From Apr 2024 to May 2024
Immutep (NASDAQ:IMMP)
Historical Stock Chart
From May 2023 to May 2024